



# Gujarat Alkalies and Chemicals Limited

(Promoted by Govt. of Gujarat)

Regd. Office & Works : P.O. Ranoli-391350, Dist. Vadodara (Gujarat) INDIA

Phone : +91-0265-6111000, 7119000 Fax : +91-0265-6111012

Website : www.gacl.com CIN NO : L24110GJ1973PLC002247

Ref. : SEC/SE/2024/

31<sup>th</sup> May, 2024

BSE Ltd. 1 <sup>st</sup> Floor, New Trading Ring Phiroze Jeejeebhoy Towers Dalal Street MUMBAI : 400 001	National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block 'G' Bandra-Kurla Complex Bandra (East) MUMBAI : 400 051
Ref. : Company Code No. : 530001	Ref. : Company Code No. : GUJALKALI

Dear Sir/Madam,

**Sub.:** Newspaper Clippings of the extract of Standalone & Consolidated audited Financial Results for the Fourth Quarter and Financial year ended on 31<sup>st</sup> March, 2024.

We refer to our letter dated 30<sup>th</sup> May, 2024 in relation to submission of Audited Financial Results of the Company (Standalone & Consolidated) for the Fourth Quarter and Financial Year ended on 31<sup>st</sup> March, 2024. In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith copies of newspaper clippings of the extract of Standalone & Consolidated audited Financial Results for Fourth Quarter and Financial Year ended on 31<sup>st</sup> March, 2024 published on 31<sup>st</sup> May, 2024 in Financial Express (All India Edition) & Financial Express (Vadodara Edition) newspapers.

We request you to kindly take note of the above.

Thanking you,

Yours faithfully,

For GUJARAT ALKALIES AND CHEMICALS LIMITED

( S S BHATT )  
COMPANY SECRETARY &  
CHIEF GENERAL MANAGER (LEGAL, CC & CSR)

E-mail . [cosec@gacl.co.in](mailto:cosec@gacl.co.in)

Encl: a/a



Dahej Complex : P.O. Dahej - 392130, Tal. Vagra, Dist. Bharuch (Gujarat) INDIA  
Phone : +91-02641-613200/613256





# Gujarat Alkalies and Chemicals Limited

(An ISO Certified Company)

(Promoted by Govt. of Gujarat)

Regd. Office: P.O. Ranoli - 391 350, Dist. Vadodara (Gujarat) INDIA.

CIN : L24110GJ1073PLC002247 | E Mail : investor\_relations@gacl.co.in; contact@gacl.co.in | Website : www.gacl.com

## EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2024

Sr. No.	Particulars	Standalone				Consolidated				(Rs. in lakhs)
		Quarter Ended		Year Ended		Quarter Ended		Year Ended		
		31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	
		Refer note 5	Refer note 5	Refer note 5	Refer note 5	Refer note 5	Refer note 5	Refer note 6	Refer note 6	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	
1	Total Income from Operations	1,00,162	1,13,812	3,80,663	4,51,650	1,00,162	1,13,812	3,80,663	4,51,650	
2	Net Profit / (Loss) for the period before Tax	(7,741)	15,546	(19,588)	86,119	(10,216)	11,461	(30,048)	69,511	
3	Net Profit / (Loss) for the period after Tax	(2,124)	11,189	(13,224)	57,570	(4,619)	7,104	(23,884)	40,962	
4	Total Comprehensive Income for the period [ Comprising profit for the period (after tax) and Other Comprehensive Income (after tax) ]	8,370	3,959	21,386	47,944	5,876	(126)	10,927	31,336	
5	Equity Share Capital (Face value per share Rs.10/-)	7,344	7,344	7,344	7,344	7,344	7,344	7,344	7,344	
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	6,27,793	6,23,702	-	-	6,00,209	6,06,578	
7	Earning Per Equity Share (of Rs. 10/- each) : (Before Other Comprehensive Income) (Not Annualised)									
	a) Basic (in Rs.)	(2.90)	15.23	(18.01)	78.39	(6.29)	9.60	(32.25)	55.78	
	b) Diluted (in Rs.)	(2.90)	15.23	(18.01)	78.39	(6.29)	9.68	(32.25)	55.78	

## Notes :

- The above results have been reviewed by the Audit Committee of Directors and approved by the Board of Directors of the Company at their meetings held on 30<sup>th</sup> May, 2024.
- The Financial Results for the quarter and Year ended 31<sup>st</sup> March, 2024 has been audited by the Statutory Auditors of the Company.
- The Company's operations fall under single segment namely "Chemicals" as per Ind AS - 108 "Segment Reporting".
- The Board of Directors of the Company has recommended Final Dividend of Rs. 13.95 per share on 7,34,36,908 Equity Shares of Rs. 10/- each, amounting to Rs. 10171.01 Lakhs as "Special Dividend".
- The figures of current quarter and quarter ended 31<sup>st</sup> March, 2023 are the balancing figures between audited figures of the full financial year ended 31<sup>st</sup> March, 2024 and 31<sup>st</sup> March, 2023 respectively and the published year to date figures upto third quarter ended 31<sup>st</sup> December, 2023 and 31<sup>st</sup> December, 2022, respectively, which were subjected to limited review.
- Other Income includes:

Particulars	Standalone				Consolidated				(Rs. in Lakhs)
	Quarter Ended		Year Ended		Quarter Ended		Year Ended		
	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	
	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	
Dividend Income	216	-	4,563	1,880	216	-	4,563	1,880	
Interest on Income Tax refund	116	60	1,539	60	116	60	1,539	60	
Insurance claim	41	-	1,099	-	41	-	1,099	-	

- Current Tax for quarter and year ended March 31, 2024 includes tax adjustment of earlier years of Rs. 45 lakhs and Rs. 134 lakhs respectively. Deferred Tax for quarter and year March 31, 2024 includes recognition of MAT credit entitlement of Rs. Nil lakhs and Rs. 856 lakhs respectively determined based on Income Tax Return for A.Y. 2023-24 filed.
- In view of the losses of Rs. 17,432.36 Lakhs incurred by Joint Venture Company, GACL - Nalco Alkalies & Chemicals Private Limited ("JV") during the year and accumulated losses of Rs. 45,972.85 Lakhs as at March 31, 2024, the Company, through external expert, has carried out impairment review of its Investment of Rs. 41,400 Lakhs in 41,40,00,000 equity shares of Rs. 10/- each in its JV. As per external expert's assessment, the fair value of above-referred Equity Investment in its JV exceeds its carrying value and consequently, it has been determined that no impairment provision needs to be recognized against carrying value of its Equity Investment held in its JV as of March 31, 2024.
- The Joint Venture Company, GACL - Nalco Alkalies & Chemicals Private Limited ("JV") has carried out impairment review of its Property, Plant and Equipment ("PPE") as of March 31, 2024, through external expert. As per external expert's assessment, Value-in-Use of PPE exceeds its carrying amounts and consequently, the management of JV has determined that no impairment provision needs to be recognized against carrying amounts of PPE as of March 31, 2024.
- The Consolidated Financial Results includes result of 60% equity Joint Venture company - GACL-NALCO Alkalies & Chemicals Pvt. Ltd. in accordance with Ind AS - 110 "Consolidated Financial Statements" and Ind AS - 28 "Investments in Associates and Joint Ventures".
- The above is an extract of the detailed format of Quarterly Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results for the fourth quarter and year ended on 31<sup>st</sup> March, 2024 are available on the Stock Exchanges website www.bseindia.com & www.nseindia.com and Company's website www.gacl.com.

By Order of the Board

Sd/-  
Swaroop P. IAS  
Managing Director  
DIN No. : 68103838Place : Gandhinagar  
Date : 30<sup>th</sup> May, 2024





# Gujarat Alkalies and Chemicals Limited

(An ISO Certified Company)

(Promoted by Govt. of Gujarat)

Regd. Office: P.O. Ranoli - 391 350, Dist. Vadodara (Gujarat) INDIA.

CIN : L24110GU1973PLC002247 | E Mail : investor\_relations@gacl.co.in; contact@gacl.co.in | Website : www.gacl.com

## EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2024

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
1	Total Income from Operations	1,00,162	1,13,812	3,80,663	4,51,850	1,00,162	1,13,812	3,80,663	4,51,850
2	Net Profit / (Loss) for the period before Tax	(7,741)	15,546	(19,588)	86,119	(10,236)	11,461	(30,048)	89,511
3	Net Profit / (Loss) for the period after Tax	(2,124)	11,189	(13,224)	57,570	(4,819)	7,104	(23,654)	40,962
4	Total Comprehensive Income for the period [ Comprising profit for the period (after tax) and Other Comprehensive Income (after tax) ]	8,370	3,959	21,386	47,944	5,876	(126)	10,927	31,336
5	Equity Share Capital (Face value per share Rs. 10/-)	7,344	7,344	7,344	7,344	7,344	7,344	7,344	7,344
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	6,27,793	6,23,702	-	-	6,00,209	6,06,578
7	Earning Per Equity Share (of Rs. 10/- each) : (Before Other Comprehensive Income) (Not Annualised)								
	a) Basic (in Rs.)	(2.90)	15.23	(18.01)	78.39	(6.29)	9.68	(32.25)	55.78
	b) Diluted (in Rs.)	(2.90)	15.23	(18.01)	78.39	(6.29)	9.68	(32.25)	55.78

### Notes :

- The above results have been reviewed by the Audit Committee of Directors and approved by the Board of Directors of the Company at their meetings held on 30<sup>th</sup> May, 2024.
- The Financial Results for the quarter and Year ended 31<sup>st</sup> March, 2024 has been audited by the Statutory Auditors of the Company.
- The Company's operations fall under single segment namely "Chemicals" as per IndAS - 108 "Segment Reporting".
- The Board of Directors of the Company has recommended Final Dividend of Rs.13.85 per share on 7,34,36,928 Equity Shares of Rs. 10/- each, amounting to Rs.10171.01 Lakhs as "Special Dividend".
- The figures of current quarter and quarter ended 31<sup>st</sup> March, 2023 are the balancing figures between audited figures of the full financial year ended 31<sup>st</sup> March, 2024 and 31<sup>st</sup> March, 2023 respectively and the published year to date figures upto third quarter ended 31<sup>st</sup> December, 2023 and 31<sup>st</sup> December, 2022, respectively, which were subjected to limited review.
- Other Income includes :

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023	31/03/2024	31/03/2023
	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
Dividend Income	216	-	4,563	1,880	216	-	4,563	1,880
Interest on Income Tax refund	116	60	1,539	60	116	60	1,539	60
Insurance claim	41	-	1,099	-	41	-	1,099	-

- Current Tax for quarter and year ended March 31, 2024 includes tax adjustment of earlier years of Rs. 45 lakhs and Rs. 134 lakhs respectively. Deferred Tax for quarter and year March 31, 2024 includes recognition of MAT credit entitlement of Rs. Nil lakhs and Rs. 658 lakhs respectively determined based on Income Tax Return for A. Y. 2023-24 filed.
- In view of the losses of Rs. 17,432.36 Lakhs incurred by Joint Venture Company, GACL - Nalco Alkalies & Chemicals Private Limited ("JV") during the year and accumulated losses of Rs. 45,972.65 Lakhs as at March 31, 2024, the Company, through external expert, has carried out impairment review of its investment of Rs. 41,400 Lakhs in 41,40,00,000 equity shares of Rs. 10/- each in its JV. As per external expert's assessment, the fair value of above-referred Equity Investment in its JV exceeds its carrying value and consequently, it has been determined that no impairment provision needs to be recognised against carrying value of its Equity Investment held in its JV as of March 31, 2024.
- The Joint Venture Company, GACL - Nalco Alkalies & Chemicals Private Limited ("JV") has carried out impairment review of its Property, Plant and Equipment ("PPE") as of March 31, 2024, through external expert. As per external expert's assessment, Value-in-Use of PPE exceeds its carrying amounts and consequently, the management of JV has determined that no impairment provision needs to be recognised against carrying amounts of PPE as of March 31, 2024.
- The Consolidated Financial Results includes result of 60% equity Joint Venture company - GACL-NALCO Alkalies & Chemicals Pvt. Ltd. in accordance with Ind AS -110 "Consolidated Financial Statements" and IndAS - 28 "Investments in Associates and Joint Ventures".
- The above is an extract of the detailed format of Quarterly Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results for the fourth quarter and year ended on 31<sup>st</sup> March, 2024 are available on the Stock Exchanges website [www.bseindia.com](http://www.bseindia.com) & [www.nseindia.com](http://www.nseindia.com) and Company's website [www.gacl.com](http://www.gacl.com)

Place : Gandhinagar  
Date : 30<sup>th</sup> May, 2024

By Order of the Board  
Sd/-  
Swaroop P. IAS  
Managing Director  
DIN No. : 08103838

xp.epapr.in

FINANCIAL EXPRESS  
READ TO LEAD

Fri, 31 May 2024

<https://epaper.financialexpress.com/c/75169898>

Ahmedabad

